Analysis of US Patent 6,858,409: Interleukin-1 Inhibitor (IL-1i) Nucleic Acids, Proteins, Host Cells, and Production Processes
US 6,858,409 claims a tightly defined family of “interleukin-1 inhibitor” (IL-1i) polypeptides, defined by a specific core amino-acid sequence with limited variability at two positions, plus nucleic acids and production systems (recombinant hosts, promoter/leader encoding, glycosylation conditions, and harvesting). The claim set is structured to obtain broad coverage across (i) nucleic acid embodiments that meet homology thresholds and (ii) expression modalities across prokaryotic and eukaryotic hosts, while retaining a narrow “anchor” sequence and specific sequence features (optional N-terminal methionine, optional amino-acid at one internal position, optional secretion leader).
What the claims actually cover
What is the core inventive content?
The claims center on an isolated nucleic acid encoding an IL-1 inhibitor polypeptide. The IL-1i polypeptide is selected from:
- A. A polypeptide comprising “all or an IL-1 inhibitory fragment” of a specific amino-acid sequence with two constrained polymorphic markers:
- (U) is M or nothing
- (X) is R or P
- B. A polypeptide that is at least ~70% homologous to the amino-acid sequence of A for Claim 1 (and higher identity/homology thresholds in dependent claims such as 80%, 90%, 95% depending on the claim).
The polypeptide sequence given in Claim 1(A) contains the same long, continuous core across the specification of subsequent claims. Dependent claims tighten the allowable variants (e.g., setting (U) to M or nothing; fixing (X) to R; increasing homology thresholds).
How broad are the homology-based gates?
The claims introduce multiple layers of homology coverage:
| Claim |
Coverage gate for “selected from” (B) |
Homology threshold stated |
| 1 |
homologous to sequence of A |
≥ about 70% |
| 2 |
nucleic acid encodes polypeptide homologous to Claim 1(A) |
≥ 80% |
| 3 |
nucleic acid encodes polypeptide homologous to Claim 1(A) |
≥ 95% |
| 5 |
selected from (B) |
≥ about 90% |
| 6 |
amino-acid sequence homologous |
≥ about 90% |
| 9 |
amino-acid sequence homologous |
≥ about 95% |
| 64 |
process recombinant polypeptide selected from (B) |
≥ about 90% |
| 65 |
amino-acid sequence homologous |
≥ about 95% |
| 66 |
amino-acid sequence homologous |
≥ about 90% |
Critical point: these percentage thresholds, without a defined alignment method, can be outcome-determinative in infringement and validity analyses. The claim language uses “homologous” and “about,” but the claims do not specify identity metrics, alignment windows, or whether the metric includes the optional N-terminal methionine or only the core length. This gives the patentee room to argue broader inclusion, while accused infringers can argue the opposite by adopting narrower alignment assumptions.
What is the sequence variability the claims permit?
The claims explicitly allow:
- Optional N-terminal M at the beginning of the IL-1i polypeptide: (U) is M or nothing.
- Two alternative residues at one position within the defined core: (X) is R or P.
- Fragments: claims cover “all or an IL-1 inhibitory fragment” of the sequence. This is typically a litigation hotspot because fragments can be treated as either broad (any sub-sequence showing IL-1 inhibition) or narrow (only fragments disclosed/structurally tied to the full sequence in the patent record).
Do the claims require IL-1 inhibition by a defined mechanism?
No. The claims require only “interleukin-1 inhibitory activity” or equivalent functional language, including Claim 80’s process functional readout (inhibits IL-1 induced PGE2 production). There is no mechanistic restriction in the independent claims for the IL-1i polypeptides beyond functional inhibition.
What expression modalities are included?
The claims extend from nucleic acid encoding IL-1i to:
- Recombinant host cells containing the DNA molecule encoding IL-1i.
- Host cells are defined broadly by capability constraints and examples:
- Not capable of glycosylation OR non-human host cell.
- Examples include yeast, mouse Ltk⁻, CHO.
- Also includes prokaryotes and specifically E. coli.
How does the glycosylation aspect shift coverage?
The landscape within the claims separates by whether host cells produce glycosylated or nonglycosylated IL-1i:
| Claim group |
Language |
| Glycosylation excluded |
“host cell is not capable of glycosylation or is a non-human host cell” |
| Produced glycosylated IL-1i |
host cell produces glycosylated IL-1i |
| Produced nonglycosylated IL-1i |
host cell produces nonglycosylated IL-1i |
This design aims to cover two biological production contexts without requiring the polypeptide to have (or not have) glycosylation motifs in the claimed IL-1i sequence itself. The coverage depends on host cell biology and process conditions.
Do the claims cover secretion leaders?
Yes. Several claims add an optional N-terminal secretion leader sequence:
- Leader AA sequence (as given):
M E I C R G L R S H L I T L L L F L F H S E T I C (Claim 19; also repeated in Claim 51/52 and process analogs)
This broadens expression to secreted IL-1i formats.
Claim-by-claim structure and legal “coverage map”
Independent claims
The dataset provided lists many dependent claims. The independent claim “anchors” are effectively:
- Claim 1: isolated nucleic acid encoding IL-1i with the sequence-defined polypeptide family (U in {M, nothing}; X in {R, P}; plus fragment coverage; plus ≥70% homologs alternative).
- Claim 5: appears to be a second nucleic-acid anchor with a more restrictive “B” homology level (≥ about 90%) and a different specific sequence block displayed in the text.
- Claim 20: recombinant host cell containing DNA encoding IL-1i.
- Claim 62: process for preparing IL-1i polypeptide by producing it in the recombinant host cell according to Claim 20; with harvesting in Claim 63.
Even without reproducing the original patent front page, the claim text you provided clearly shows the independent claims and the incremental tightening logic in dependents.
Dependent claims tighten identity and operational parameters
The claims follow a consistent tightening pattern:
-
Identity/homology tightening
Examples: 80%, 90%, 95% gates.
-
Variant fixation of (U) and/or (X)
Examples: (X) fixed to R; (U) fixed to M; (U) fixed to nothing.
-
Definition of nucleic acid features
Examples: heterologous promoter linkage; secretion leader inclusion.
-
Host cell constraints
Examples: non-glycosylating/non-human; prokaryotic and eukaryotic examples (yeast, CHO, mouse Ltk⁻, E. coli).
-
Product post-production context
Examples: glycosylated vs nonglycosylated IL-1i production.
Critical assessment of claim strength and litigation posture
Where the claim set is strongest
-
Sequence anchoring
The polypeptide family is anchored to a long specific amino-acid sequence with only two stated variable points: (U) and (X). This reduces prior art risk relative to broader cytokine inhibitor classes defined only functionally.
-
Multi-layer coverage
The claims cover:
- nucleic acids,
- polypeptides (by encoding),
- recombinant host cells,
- processes, including harvesting,
- secretion leader inclusion,
- and glycosylation outcome via host cell selection.
-
Homology gradation
Multiple dependent claims use 70%, 80%, 90%, 95% homology thresholds. That offers fallback positions in validity or narrowing constructions.
Where the claim set is vulnerable
-
Homology ambiguity
Terms like “homologous” and “at least about” invite construction disputes:
- Does the comparison include conservative substitutions?
- How are gaps handled?
- Is it calculated on full-length polypeptide including optional residues?
- What alignment algorithm would a court use?
In infringement litigation, accused infringers can target the boundary case between 89% and 90% (or 94% and 95%) while in validity, a prior art sequence can be characterized to fall just outside thresholds.
-
Fragment coverage breadth
“All or an IL-1 inhibitory fragment” invites disputes on:
- how large a fragment must be,
- whether any sub-sequence can qualify if it has IL-1 inhibitory activity,
- and whether the claim is limited to fragments disclosed in the specification or structurally tied to the full-length IL-1i.
-
Functional language without mechanistic limitation
“IL-1 inhibitory activity” can overlap with prior art proteins or peptides that inhibit IL-1 via different binding epitope or pathway. If the prior art discloses sequences not identical but functionally overlapping, homology thresholds become the key battlefield.
-
Glycosylation and host capability may not correlate cleanly
Claims tie glycosylation outcome to host cell function (“not capable of glycosylation or non-human host cell” plus downstream dependent claims on glycosylated vs nonglycosylated production). Accused infringers may argue:
- glycosylation depends on post-translational motifs,
- and host cell glycosylation capability may not map cleanly onto claimed polypeptide structure.
Practical competitive implications: how to evaluate freedom-to-operate (FTO) around this patent
What design-around levers exist based on claim text
Given the explicit toggles (U in {M, none}; X in {R, P}; “fragment”; and “homology %” gates), design-around efforts typically hinge on:
- Changing the residue at the (X) position from the allowed set (R/P) to another amino acid.
- Eliminating or altering the N-terminal M optionality such that the polypeptide no longer falls within the homology window (especially if the alignment algorithm includes the optional residue).
- Escaping homology thresholds by ensuring the candidate polypeptide is <70%, <80%, <90%, or <95% homologous depending on which claim is targeted.
- Avoiding secretion leader formats if the relevant claims in the target portfolio rely on the leader.
- Choosing host systems strategically to minimize overlap with “not capable of glycosylation” limitations or with any host examples that are used as anchors.
Where competitors are likely to collide
Collisions are most probable if a candidate product:
- uses the same core IL-1i sequence with only R/P at the (X) position and M/none at (U), or
- keeps high similarity above 90% or 95% to the exact anchored sequences, or
- encodes via nucleic acids and production methods that match host and secretion leader options.
Patent landscape review: what can be concluded from the claim set provided
What the landscape likely looks like structurally
For a patent structured like this, the relevant competitive landscape generally clusters around:
- the IL-1 inhibitor polypeptide itself (sequence-defined core),
- the encoding nucleic acid (often corresponding to codons but constrained by sequence),
- and the expression system (secretory leader usage; glycosylation vs non-glycosylation; prokaryotic vs eukaryotic host choices).
However, a true multi-family landscape requires citation-level data: other US applications, PCT publications, granted continuations, reissues, oppositions, and assignment history. That information is not included in the prompt.
Key Takeaways
- US 6,858,409 claims IL-1 inhibitor nucleic acids that encode a sequence-anchored IL-1i polypeptide family with limited explicit variability: (U)=M or nothing and (X)=R or P (plus “all or IL-1 inhibitory fragment” coverage).
- The claim set’s breadth comes from homology thresholds (notably ≥70% in Claim 1 and ≥80%/90%/95% across dependents), creating a litigation boundary around high-percentage identity.
- Coverage extends beyond molecules to recombinant host cells and processes, including optional heterologous promoter and N-terminal secretion leader sequences and dependent glycosylation outcome claims.
- The main validity and infringement vulnerabilities in the claim text are homology-method ambiguity and fragment breadth.
- For FTO, the strongest design-around levers are changes that push candidates below the relevant homology thresholds, eliminate allowed (X) residue options, or avoid secretion leader/production embodiments that map to dependent claim sets.
FAQs
-
Do the claims require the IL-1i polypeptide to be full-length?
No. The claims include “all or an IL-1 inhibitory fragment” of the anchored amino-acid sequence, subject to IL-1 inhibitory activity and homology coverage constructs.
-
Which two explicit amino-acid variability points drive coverage across claims?
The claim text repeatedly defines (U) as M or nothing and (X) as R or P within the anchored sequence; dependent claims also fix those values.
-
What homology thresholds matter most for product design and claim targeting?
The dataset lists 70% (Claim 1), 80% (Claim 2), 90% (Claim 5 and related dependents), and 95% (Claim 3 and related dependents). The relevant threshold depends on the specific claim being asserted.
-
Are secretion leader sequences part of the core invention or only dependent coverage?
The leader is introduced in dependent claims (e.g., Claim 19 and related process/host analogs), so it expands coverage for secreted expression formats but is not the only route in the independent claim framework.
-
Does glycosylation status determine whether the claims apply?
The claims include both glycosylated and nonglycosylated production outcomes and also constrain host cell capability (not capable of glycosylation or non-human). Glycosylation therefore acts as a dependent-coverage lever tied to host biology rather than an absolute structural exclusion.
References
[1] United States Patent 6,858,409 (claim text provided in prompt).
